Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.

abstract：INTRODUCTION:Stiripentol and vigabatrin are the two anticonvulsant drugs currently approved in severe infantile-onset epilepsies, respectively Dravet syndrome and infantile spasms. AREAS COVERED:For both, the indication was discovered by chance thanks to an exploratory study. Both demonstrated indisputable efficacy th...

journal_title：Expert opinion on pharmacotherapy

authors： Chiron C

更新日期：2016-06-01 00:00:00

abstract：:Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective endothelin-A receptor antagonist, is an effective, safe and well-tolerated endothelin receptor antagonist for the treatment of PAH in adult patients. Multi-center, randomized, placebo-controlled clinical trials...

journal_title：Expert opinion on pharmacotherapy

authors： Barst RJ

更新日期：2007-01-01 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is a rare disease characterized by the accumulation of clonal dendritic cells in different organs. Most recent findings (e.g., activating BRAF mutations) favor the hypothesis that LCH may represent a neoplasm with varying behavior, but the ultimate pathogenesis remains to be uncover...

journal_title：Expert opinion on pharmacotherapy

authors： Minkov M

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:Myoclonic seizures are brief, involuntary muscular jerks arising from the central nervous system that can occur in different epilepsy syndromes, including idiopathic generalized epilepsies or the most severe group of epileptic encephalopathies. Valproate is commonly the first choice alone or in combination...

journal_title：Expert opinion on pharmacotherapy

authors： Striano P,Belcastro V

更新日期：2017-02-01 00:00:00

abstract：:Fluticasone propionate (FP) is a potent inhaled corticosteroid (ICS) for the treatment of asthma. It is currently marketed in both the United States (as Flovent) and Europe (as Flixotide). Fluticasone is available in both aerosolised metered dose inhaler (MDI) and dry powder devices, with dosages ranging from 44-500 m...

journal_title：Expert opinion on pharmacotherapy

authors： Staresinic AG,Sorkness CA

更新日期：2000-09-01 00:00:00

abstract：INTRODUCTION:Glaucoma is the second leading cause of blindness globally, representing a significant public health concern. More than 60 million people are affected by glaucoma worldwide; as this population ages, the number is expected to increase. Glaucoma is a collection of heterogeneous diseases sharing common clinic...

journal_title：Expert opinion on pharmacotherapy

authors： Konstas AG,Quaranta L,Realini T

更新日期：2012-04-01 00:00:00

abstract：:Selective serotonin reuptake inhibitors (SSRIs) are now generally regarded as effective and better tolerated alternatives to tricyclic antidepressants (TCAs) for the treatment of depression. SSRIs also seem to be as well tolerated as moclobemide, mirtazapine, venlafaxine, reboxetine and nefazodone and show comparable ...

journal_title：Expert opinion on pharmacotherapy

authors： Mace S,Taylor D

更新日期：2000-07-01 00:00:00

abstract：INTRODUCTION:Adjunctive pharmacotherapy is of key importance in determining the outcomes of percutaneous coronary intervention (PCI). In parallel, there has been an increasing body of evidence indicating that the aggressive management of coronary risk factors and changes in lifestyle behavior yield additional positive ...

journal_title：Expert opinion on pharmacotherapy

authors： Capodanno D,Tamburino C,Dangas G

更新日期：2011-05-01 00:00:00

abstract：OBJECTIVE:To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). RESEARCH DESIGN AND METHODS:Post hoc analysis o...

journal_title：Expert opinion on pharmacotherapy

authors： Hargarter L,Bergmans P,Cherubin P,Keim S,Conca A,Serrano-Blanco A,Bitter I,Bilanakis N,Schreiner A

更新日期：2016-06-01 00:00:00

abstract：INTRODUCTION:Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system involving inflammation, chronic demyelination and axonal loss. MS affects more than 2 million people worldwide. AREAS COVERED:This article aims to summarize the findings from two pivotal 2-year, randomized, do...

journal_title：Expert opinion on pharmacotherapy

authors： Havrdova E,Hutchinson M,Kurukulasuriya NC,Raghupathi K,Sweetser MT,Dawson KT,Gold R

更新日期：2013-10-01 00:00:00

abstract：:Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in...

journal_title：Expert opinion on pharmacotherapy

authors： Ward EM,Wolfsen HC

更新日期：2003-03-01 00:00:00

abstract：INTRODUCTION:Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central nervous system affecting both white matter and grey matter in the earliest phases of its course. The crucial role of neurodegeneration in disability progression in MS, regardless of white matter damage, has been confirm...

journal_title：Expert opinion on pharmacotherapy

authors： Pitteri M,Magliozzi R,Bajrami A,Camera V,Calabrese M

更新日期：2018-03-01 00:00:00

abstract：:Despite the revolutionary introduction of antibiotic therapy in the post-World War II era, primary care physicians continue to struggle with the issue of optimal treatment strategies for bacterial infection and the growing problem of antimicrobial resistance. The aggressive use of potent agents as first-line therapy m...

journal_title：Expert opinion on pharmacotherapy

authors： Nicolau DP

更新日期：2004-02-01 00:00:00

abstract：:The objective of this article is to evaluate the roles of the lipid-lowering class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in reducing cardiovascular events and to review their mechanism of action based on in vitro and in vivo studies. The clinical outcome of 15 major clinical...

journal_title：Expert opinion on pharmacotherapy

authors： Moghadasian MH,Mancini GB,Frohlich JJ

更新日期：2000-05-01 00:00:00

abstract：INTRODUCTION:Phosphodiesterase type 5 inhibitors (PDE5-i) are used for the oral treatment of erectile dysfunction (ED). Since the launch of sildenafil more than 15 years ago, new molecules have become available. At present, in addition to tadalafil and vardenafil, there are three other drugs, udenafil, avanafil and mir...

journal_title：Expert opinion on pharmacotherapy

authors： Bruzziches R,Francomano D,Gareri P,Lenzi A,Aversa A

更新日期：2013-07-01 00:00:00

abstract：INTRODUCTION:During the past decade, there have been significant advances in the pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently available treatment options, anti-vascular endothelial growth factors (anti-VEGF) agents are the most favored agents due to their efficacy and safety....

journal_title：Expert opinion on pharmacotherapy

authors： Agarwal A,Parriott J,Demirel S,Argo C,Sepah YJ,Do DV,Nguyen QD

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Clostridium difficile has become the most important healthcare-associated infection worldwide within the past decade. This is in part due to the emergence of a highly virulent epidemic strain of C. difficile as well as the relative ineffectiveness of current therapies at producing a sustained response. Fid...

journal_title：Expert opinion on pharmacotherapy

authors： Hostler CJ,Chen LF

更新日期：2013-08-01 00:00:00

abstract：INTRODUCTION:Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepi...

journal_title：Expert opinion on pharmacotherapy

authors： Striano P,Belcastro V

更新日期：2013-07-01 00:00:00

abstract：:The purine nucleoside analogues, either alone or in combination with other chemotherapeutic agents, are increasingly used in the treatment of patients with indolent B-cell lymphoproliferative disorders. The initial studies in Waldenström's macroglobulinaemia (WM) are very promising. Approximately 40% of patients who h...

journal_title：Expert opinion on pharmacotherapy

authors： Owen RG

更新日期：2001-06-01 00:00:00

abstract：:Migraine is a common and disabling condition in children and adolescents. The complexity of migraine on a pathogenetic and clinical level results from the interaction between biological, psychological and environmental factors. Appropriate management requires an individually tailored strategy giving due consideration ...

journal_title：Expert opinion on pharmacotherapy

authors： Balottin U,Termine C

更新日期：2007-04-01 00:00:00

abstract：INTRODUCTION:Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk of both systemic cardiovascular adverse events and limb-related morbidity. There is insufficient awareness of ...

journal_title：Expert opinion on pharmacotherapy

authors： Essa H,Torella F,Lip GYH

更新日期：2020-09-01 00:00:00

abstract：INTRODUCTION:Etravirine (TMC125) is an orally administered second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved in treatment-experienced patients as addition to an optimized background therapy (OBT). AREAS COVERED:A Medline search was conducted of Phase II - IV clinical trials, as ...

journal_title：Expert opinion on pharmacotherapy

authors： Schrijvers R

更新日期：2013-06-01 00:00:00

abstract：BACKGROUND:Fesoterodine is a newly approved drug for the treatment of overactive bladder syndrome. OBJECTIVE:The aim of this study was to review the preclinical and clinical data on fesoterodine. METHODS:The study involved a search of the Medline database and the proceedings volumes of urological congresses. RESULTS...

journal_title：Expert opinion on pharmacotherapy

authors： Michel MC

更新日期：2008-07-01 00:00:00

abstract：:There has been an increase in the incidence and prevalence of gout in the past several decades. A distinction needs to be made between the treatment of gout as an acute inflammatory disease and the lowering of the serum urate (SU) levels into a normal range. Treating acute gout attacks alone is not sufficient to preve...

journal_title：Expert opinion on pharmacotherapy

authors： Schlesinger N,Dalbeth N,Perez-Ruiz F

更新日期：2009-06-01 00:00:00

abstract：:Elevated blood pressure levels are highly prevalent and are a major reason for cardiovascular events and thus place a significant financial burden on healthcare systems worldwide. Guidelines recommend five first-line anti-hypertensive drug classes, but compelling indications may indicate favoring one drug class over a...

journal_title：Expert opinion on pharmacotherapy

authors： Bramlage P,Durand-Zaleski I,Desai N,Pirk O,Hacker C

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:The pharmacotherapeutic management of depression in patients with multiple sclerosis (MS) is a matter of debate that cannot be decided from the evidence available in the current literature. Therefore, its management essentially relies on the clinical experience of the prescribing clinician rather than on e...

journal_title：Expert opinion on pharmacotherapy

authors： Carta MG,Paribello P,Anastasia A,De Berardis D,Nardi AE,Fornaro M

更新日期：2018-10-01 00:00:00

abstract：:Valproic acid (VPA) is considered to be a drug of first choice and one of the most frequently-prescribed antiepileptic drugs worldwide for the therapy of generalized and focal epilepsies, including special epileptic. It is a broad-spectrum antiepileptic drug and is usually well tolerated. Rarely, serious complications...

journal_title：Expert opinion on pharmacotherapy

authors： Gerstner T,Bell N,König S

更新日期：2008-02-01 00:00:00

abstract：INTRODUCTION:Aripiprazole long acting once-monthly (AOM) is approved for the treatment of schizophrenia in adults. Despite recent evidence of AOM efficacy in the acute treatment of schizophrenia, it is recommended that AOM should be started once the acute symptoms are controlled and patients are stabilized. However, th...

journal_title：Expert opinion on pharmacotherapy

authors： Amodeo G,Candiracci C,Capecci I,De Filippis S,Giuliani S,Guerani G,Tomasetti C,Villari V,Fagiolini A

更新日期：2016-11-01 00:00:00

abstract：INTRODUCTION:Metastatic prostate cancer is an incurable disease that is treated with a variety of hormonal therapies targeting various nodes of the androgen receptor (AR) pathway. Invariably patients develop resistance and become castration resistant. Common treatments for castration-resistant disease include novel hor...

journal_title：Expert opinion on pharmacotherapy

authors： Maughan BL,Antonarakis ES

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Generalized anxiety disorder (GAD) is a chronic, relapsing, debilitating disorder, associated with markedly impaired social and occupational functioning. Pharmacological treatment is considered standard care and several drug classes are now FDA approved for the treatment of GAD. While there are clear data ...

journal_title：Expert opinion on pharmacotherapy

authors： Reinhold JA,Mandos LA,Rickels K,Lohoff FW

更新日期：2011-11-01 00:00:00